AH Capital Management L.L.C. Trims Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

AH Capital Management L.L.C. decreased its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108,568 shares of the company's stock after selling 4,234,181 shares during the period. Ginkgo Bioworks comprises about 0.1% of AH Capital Management L.L.C.'s investment portfolio, making the stock its 12th biggest position. AH Capital Management L.L.C. owned 0.20% of Ginkgo Bioworks worth $885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently made changes to their positions in the company. AQR Capital Management LLC purchased a new stake in Ginkgo Bioworks in the second quarter worth approximately $3,391,000. Monaco Asset Management SAM purchased a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at $3,276,000. Renaissance Technologies LLC purchased a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at $2,128,000. Cetera Investment Advisers grew its holdings in shares of Ginkgo Bioworks by 2,683.7% during the 1st quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company's stock valued at $2,626,000 after purchasing an additional 2,182,773 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Ginkgo Bioworks in the 2nd quarter worth $312,000. Hedge funds and other institutional investors own 78.63% of the company's stock.

Ginkgo Bioworks Trading Up 3.8 %

Ginkgo Bioworks stock traded up $0.30 during trading hours on Wednesday, reaching $8.25. The stock had a trading volume of 543,025 shares, compared to its average volume of 1,147,637. The company's fifty day simple moving average is $7.90. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $75.20. The stock has a market cap of $474.21 million, a PE ratio of -0.62 and a beta of 1.09.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DNA. BTIG Research raised their price objective on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a research note on Friday, August 23rd. TD Cowen raised their price target on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.